Table 1. Demographic and laboratory characteristics of patients with pancreatic neuroendocrine neoplasms (pNENs).
| Parameter | FU (n=15) | SR (n=21) | ST (n=15) |
|---|---|---|---|
| Male/Female (n) | 6/9 | 7/14 | 7/8 |
| Age, no. of years | 65 (27-84) | 52 (27-82) | 72 (27-87) |
| TNM stage (no. of pts) | |||
| I | 14 | 2 | - |
| II | 1 | 9 | 7 |
| III | - | 1 | - |
| IV | - | 9 | 8 |
| Size (mm) | 11 (7-20) | 22 (8-60) | 26 (20-60) |
| Grade (G1/G2/G3) | 15/0/0 | 10/10/1 | 8/5/2 |
| Functioning yes/no (no. of pts) | -/15 | 6/15 | 5/10 |
| MEN1 (no. of cases) | 3 | 5 | 2 |
| Follow-up (no. of months) | 36 (5-58) | 57 (13-84) | 27 (2-84) |
| Chromogranin A (U/L) | 40 (12-267) | 28 (9-3240) | 136 (19-1236) |
Data are expressed as median (and range) unless specified otherwise.
G1: neuroendocrine tumor with Ki-67 ≤2%; G2: neuroendocrine tumor with Ki-67 between 3 and 20%; G3: NEN with Ki-67 >20%